Good morning, and welcome to Auris Medical's Conference Call. On today's call are Thomas Meyer, Auris Medical's Chairman and Chief Executive Officer; and Elmar Schaerli, Auris Medical's Chief Financial Officer, who will present the company's financial results for the first half of 2020 and provide a business update. The accompanying slides can be found on our website in the Investors section. Earlier today, Auris Medical issued a news release with the first half 2020 financial results as well as a business update. The release is available on the company's website, aurismedical.com and filed with the SEC.
During today's call, we'll be making forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These include statements that address future operating, financial or business performance or our strategies or expectations. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements.
These risks and uncertainties include, but are not limited to, the timing and conduct of our clinical trials, the clinical utility of our product candidates, the timing or likelihood of regulatory filings and approvals, our intellectual property position and our financial position as well as those described in the Risk Factors section in our annual report on Form 20-F and future filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. While we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so even if our views change.
With that, I'll hand the call over to Thomas Meyer.
Thank you, Elaine. Hello, everyone and thank you for taking the time to join Auris Medical's first half 2020 earnings and business update call. On the call, I will provide an update on our various development projects, as well as an overview of recent corporate developments. Following my update, our CFO, Elmar Schaerli will provide an overview of our first half financials. Finally, I will discuss key milestones for 2020 and leading into 2021. We will then open the call for any questions.
In the past few months, we continue to make significant progress with our clinical-stage intranasal betahistine program, announcing positive results in our two main projects, AM-125 and AM-201. In terms of some key highlights, we announced that we will be advancing our Phase 2 trial with AM-125 for acute vertigo following the positive interim data that we recently announced. And we reported positive outcomes in our Phase 1b trial with AM-201 for the reduction of antipsychotic-induced weight gain. We are also happy to report that betahistine administered intranasally showed good safety and tolerability in both programs. I'll discuss the exciting data from these trials shortly.
In addition to our betahistine programs, we recently established a new program AM-301, a
Chief Executive Officer
Chief Financial Officer
We are pleased that you like our content! Sign Up now to access premium content for free, a very limited time offer.
Welcome! Create your account
You are successfully registered!
An activation link has been sent to your mail. Please activate and login.